Oncotelic transfers N2B delivery assets to Lunai Bioworks for $12.5 million stock

ONCOTELIC THERAPEUTICS INC

ONCOTELIC THERAPEUTICS INC

OTLC

0.00
  • Oncotelic Therapeutics closed strategic transfer of its N2B nose-to-brain delivery system assets to Lunai Bioworks, receiving USD 12.5 million in Lunai Bioworks Series B Convertible Preferred Stock.
  • Lunai Bioworks secured worldwide rights to N2B intellectual property within defined fields limited to biodefense medical countermeasures and Alzheimer’s disease.
  • Oncotelic retained rights to develop N2B outside those fields, including Parkinson’s disease and sexual dysfunction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060830PRIMZONEFULLFEED9714133) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.